MIL62, a treatment approved in China to treat neuromyelitis optica spectrum disorder (NMOSD), was superior to a placebo…
Articles by Andrea Lobo
Children with neuromyelitis optica spectrum disorder (NMOSD) are more likely to have severe vision problems and incomplete visual recovery…
A specialized MRI measure used as a proxy of the brain’s waste-clearing system may help monitor disease severity and progression…
A short-course of Soliris (eculizumab) treatment during relapses may help people with neuromyelitis optica spectrum disorder (NMOSD) recover…
Use of the approved therapy Uplizna (inebilizumab) reduces the risk of relapse and worsening disability in people with…
For a rare group of neuromyelitis optica spectrum disorder (NMOSD) patients who test negative for two self-reactive antibodies, being…
Soliris (eculizumab) is linked to a reduced relapse rate and stabilization of disability progression in people with neuromyelitis…
Enspryng (satralizumab) is superior to conventional immunosuppressive therapies in reducing the risk of relapses in people with neuromyelitis…
People with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of chitotriosidase-1 (CHIT1), a protein involved in immune and…
Ofatumumab, a medication approved for multiple sclerosis (MS), may effectively prevent relapses and disability in people with neuromyelitis optica…